Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Needham starts Revance Therapeutics at buy; PT $42

Needham initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $42 price target. The stock closed at $30.60 on March 26. Revance is involved in the development of novel and differentiated...

March 27, 2018

Markets

Stifel cuts Protagonist Therapeutics to hold; PT to $11 from $32

Stifel downgraded Protagonist Therapeutics (NASDAQ:PTGX) to “hold” from “buy” and slashed its price target to $11 from $32 after the company discontinued its Phase 2b PROPEL study of PTG-100 in patients with moderate-to...

March 26, 2018

Markets

Roth downgrades NovaBay Pharma to neutral; PT to $4 from $5

Roth Capital Partners downgraded NovaBay Pharmaceuticals (NYSE American:NBY) to “neutral” from “buy” and lowered its price target to $4 from $5, pending renewed prescription growth for the eyelid hygiene treatment...

March 26, 2018

Markets

Paradigm ups Profound Medical PT to $3

Paradigm Capital raised its price target for Profound Medical (TSXV:PRN) to $3 from $2.25 after the company completed an upsized equity financing of $34.5-million. The stock closed at $1.05 on March 20. “We see this...

March 21, 2018

Markets

Profound Medical closes upsized bought deal financing

Profound Medical (TSXV:PRN) closed a previously announced bought deal financing for gross proceeds of $34.5-million, including the exercise of the underwriters’ over-allotment option. Net proceeds are expected to be...

March 20, 2018

Markets

Maxim ups Sellas Life Sciences to buy; PT $13

Maxim Group upgraded Sellas Life Sciences (NASDAQ:SLS) to “buy” from “hold,” with a $13 price target after meeting with Sellas management. The stock closed at $4.79 on March 16. Sellas completed a merger with Galena...

March 19, 2018

Markets

Piper upgrades Nuvectra to OW; PT to $16

Piper Jaffray upgraded Nuvectra (NASDAQ:NVTR) to “overweight” from “neutral” and raised its price target to $16 from $12 after the company reported fourth quarter results. The stock closed at $11.69 on March 15. The...

March 16, 2018

Markets

VolitionRx closes $8.4-million stock offering

VolitionRx (NYSE American:VNRX) closed an offering of 3.5 million common shares at a price of $2.40 a share for gross proceeds of $8.4-million. Volition, which develops blood tests to help diagnose a range of cancers...

March 14, 2018

Markets

Mackie starts Acerus Pharma at speculative buy; PT 50 cents

Mackie Research Capital initiated coverage of Acerus Pharmaceuticals (TSX:ASP) with a “speculative buy” rating and a 12-month target price of 50 cents. The stock closed at 26 cents on March 13. Acerus specializes in men...

March 14, 2018

Markets

Piper starts Motus GI at OW; PT $7

Piper Jaffray initiated coverage of Motus GI Holdings (NASDAQ:MOTS) with an “overweight” rating and $7 price target. The stock closed at $4.98 on March 9. The company’s Pure-Vu device makes the prep regimen for...

March 12, 2018

Markets

Maxim cuts Can-Fite Biopharma to hold; removes PT

Maxim Group downgraded Can-Fite Biopharma (NYSE American:CANF) to “hold” from “buy” and removed its previous $7 price target after the company announced a $5-million registered direct offering. The stock was quoted at...

March 9, 2018

Markets

Roth doubles Juniper Pharma PT to $24

Roth Capital Partners doubled its price target for Juniper Pharmaceuticals (NASDAQ:JNP) to $24 from $12 after the company reported 2017 results. The stock closed at $10 on March 9. Juniper is focused on developing...

March 9, 2018

Markets

Roth starts Myomo at buy; PT $9

Roth Capital Partners initiated coverage of Myomo (NYSE American:MYO) with a “buy” rating and $9 price target. The stock closed at $4.15 on March 8. Analyst Scott Henry writes that the MyoPro robotic arm brace offers...

March 9, 2018

Markets

Stifel ups Dicerna Pharma PT to $17 from $10

Stifel raised its price target for Dicerna Pharmaceuticals (NASDAQ:DRNA) to $17 from $10 after the company reported fourth quarter results. The stock closed at $13.50 on March 18. Dicerna is a leading developer of...

March 9, 2018

Markets

Roth starts coverage of 3 companies with novel approaches to AD

Roth Capital Partners initiated coverage of three companies – vtv Therapeutics (NASDAQ:VTVT), Anevex Life Sciences (NASDAQ:AVXL) and Neurotrope Biosciences (NASDAQ:NTRP) – that are developing drugs with novel...

March 9, 2018

Markets

Leerink cuts American Renal to MP but ups PT to $27

Leerink downgraded American Renal Associates (NYSE:ARA) to “market perform” but raised its price target to $27 from $17, citing a fuller valuation after the company reported fourth quarter results. The stock closed at...

March 8, 2018

Markets

CIBC ups Theratechnologies PT to $15 from $10.30

CIBC World Markets raised its price target for Theratechnologies (TSX:TH) to $15 from $10.30 after the FDA approved Trogarzo for the treatment of multi-drug resistant HIV patients. The stock was quoted at $9.35 in...

March 7, 2018

Markets

Maxim lowers BioLineRx PT to $2 from $3

Maxim Group reduced its price target for BioLineRx (NASDAQ:BLRX) to $2 from $3 after the company reported fourth quarter results. The stock was quoted at $1 in afternoon trading on March 6. BioLineRx, which focuses on...

March 6, 2018

Markets

BTIG cuts Obalon Therapeutics PT to $7 from $13

BTIG lowered its price target for Obalon Therapeutics (NASDAQ:OBLN) to $7 from $13 after the company reported in-line fourth quarter results and guidance for 2018. The stock finished at $4.01 on March 5. Obalon is...

March 6, 2018

Markets

BTIG ups Vericel PT to $13 from $8

BTIG raised its price target for Vericel (NASDAQ:VCEL) to $13 from $8 after the company beat consensus estimates for the fourth quarter and provided strong guidance for 2018. The stock was quoted at $11.15, up $2.80, in...

March 5, 2018

Markets

Stifel nearly triples PT for GTx to $45 from $16

Stifel nearly tripled its price target for GTx (NASDAQ:GTXI) to $45 from $16 after the company reported significant positive new data at the SUFU Winter Meeting for its Phase 2 proof-of-concept study testing, enobosarm...

March 5, 2018

Markets

Ladenburg starts Intec Pharma at buy; PT $13

Ladenburg Thalmann launched coverage of Intec Pharma (NASDAQ:NTEC) with a “buy” rating and $13 price target. The stock was quoted at $6 in early trading on March 1. Intec is leveraging its proprietary drug delivery...

March 1, 2018

Subscribe